784 related articles for article (PubMed ID: 25199012)
21. Outcomes of MDR/XDR-TB patients treated with linezolid: experience in Thailand.
Roongruangpitayakul C; Chuchottaworn C
J Med Assoc Thai; 2013 Oct; 96(10):1273-82. PubMed ID: 24350407
[TBL] [Abstract][Full Text] [Related]
22. Extensively drug-resistant tuberculosis in california, 1993-2006.
Banerjee R; Allen J; Westenhouse J; Oh P; Elms W; Desmond E; Nitta A; Royce S; Flood J
Clin Infect Dis; 2008 Aug; 47(4):450-7. PubMed ID: 18616396
[TBL] [Abstract][Full Text] [Related]
23. Concomitant increases in spectrum and level of drug resistance in Mycobacterium tuberculosis isolates.
Sun Z; Zhang J; Song H; Zhang X; Li Y; Tian M; Liu Y; Zhao Y; Li C
Int J Tuberc Lung Dis; 2010 Nov; 14(11):1436-41, i. PubMed ID: 20937184
[TBL] [Abstract][Full Text] [Related]
24. Mycobacterial interspersed repetitive unit typing and mutational profile for multidrug-resistant and extensively drug-resistant tuberculosis surveillance in Portugal: a 3-year period overview.
Silva C; Perdigão J; Jordão L; Portugal I
Int J Antimicrob Agents; 2014 Dec; 44(6):546-51. PubMed ID: 25270633
[TBL] [Abstract][Full Text] [Related]
25.
Leechawengwongs M; Prammananan T; Jaitrong S; Billamas P; Makhao N; Thamnongdee N; Thanormchat A; Phurattanakornkul A; Rattanarangsee S; Ratanajaraya C; Disratthakit A; Chaiprasert A
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061759
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of multidrug and extensively drug-resistant tuberculosis in Beijing, China: a hospital-based retrospective study.
Wang D; Yang C; Kuang T; Lei H; Meng X; Tong A; He J; Jiang Y; Guo F; Dong M
Jpn J Infect Dis; 2010 Sep; 63(5):368-71. PubMed ID: 20859008
[TBL] [Abstract][Full Text] [Related]
27. Acquired Drug Resistance in Mycobacterium tuberculosis and Poor Outcomes among Patients with Multidrug-Resistant Tuberculosis.
Kempker RR; Kipiani M; Mirtskhulava V; Tukvadze N; Magee MJ; Blumberg HM
Emerg Infect Dis; 2015 Jun; 21(6):992-1001. PubMed ID: 25993036
[TBL] [Abstract][Full Text] [Related]
28. Drug Resistance Characteristics of
Wu X; Yang J; Tan G; Liu H; Liu Y; Guo Y; Gao R; Wan B; Yu F
Front Cell Infect Microbiol; 2019; 9():345. PubMed ID: 31828045
[No Abstract] [Full Text] [Related]
29. Classical against molecular-genetic methods for susceptibility testing of antituberculotics.
Porvaznik I; Mokry J; Solovic I
Adv Exp Med Biol; 2015; 835():15-22. PubMed ID: 25252893
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of drug resistance in Mycobacterium tuberculosis.
Zhang Y; Yew WW
Int J Tuberc Lung Dis; 2009 Nov; 13(11):1320-30. PubMed ID: 19861002
[TBL] [Abstract][Full Text] [Related]
31. In vitro activity of linezolid against multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant (XDR)-TB isolates.
Prammananan T; Chaiprasert A; Leechawengwongs M
Int J Antimicrob Agents; 2009 Feb; 33(2):190-1. PubMed ID: 18945598
[No Abstract] [Full Text] [Related]
32. Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Beijing, China: 2006 versus 2012.
Yin QQ; Jiao WW; Li QJ; Xu F; Li JQ; Sun L; Li YJ; Huang HR; Shen AD
BMC Microbiol; 2016 May; 16():85. PubMed ID: 27176471
[TBL] [Abstract][Full Text] [Related]
33. [Investigation of extensive drug resistance in multidrug resistance tuberculosis isolates].
Bektöre B; Haznedaroğlu T; Baylan O; Ozyurt M; Ozkütük N; Satana D; Cavuşoğlu C; Seber E
Mikrobiyol Bul; 2013 Jan; 47(1):59-70. PubMed ID: 23390903
[TBL] [Abstract][Full Text] [Related]
34. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis.
Nam HS; Koh WJ; Kwon OJ; Cho SN; Shim TS
Int J Antimicrob Agents; 2009 Jan; 33(1):92-3. PubMed ID: 18789655
[No Abstract] [Full Text] [Related]
35. Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012.
Chang KC; Yew WW
Respirology; 2013 Jan; 18(1):8-21. PubMed ID: 22943408
[TBL] [Abstract][Full Text] [Related]
36. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years.
Huang TS; Liu YC; Sy CL; Chen YS; Tu HZ; Chen BC
Antimicrob Agents Chemother; 2008 Jun; 52(6):2226-7. PubMed ID: 18391030
[TBL] [Abstract][Full Text] [Related]
37. Multidrug-resistant and extensively drug-resistant tuberculosis in the West. Europe and United States: epidemiology, surveillance, and control.
Migliori GB; D'Arcy Richardson M; Sotgiu G; Lange C
Clin Chest Med; 2009 Dec; 30(4):637-65, vii. PubMed ID: 19925959
[TBL] [Abstract][Full Text] [Related]
38. Surveillance of drug-resistant tuberculosis in the state of Gujarat, India.
Ramachandran R; Nalini S; Chandrasekar V; Dave PV; Sanghvi AS; Wares F; Paramasivan CN; Narayanan PR; Sahu S; Parmar M; Chadha S; Dewan P; Chauhan LS
Int J Tuberc Lung Dis; 2009 Sep; 13(9):1154-60. PubMed ID: 19723407
[TBL] [Abstract][Full Text] [Related]
39. Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance.
Alame-Emane AK; Xu P; Pierre-Audigier C; Cadet-Daniel V; Shen X; Sraouia M; Siawaya JF; Takiff H; Gao Q; Gicquel B
Int J Tuberc Lung Dis; 2015 Jun; 19(6):679-84. PubMed ID: 25946359
[TBL] [Abstract][Full Text] [Related]
40. Resistance patterns of multidrug-resistant tuberculosis in Western Province, Papua New Guinea.
Simpson G; Coulter C; Weston J; Knight T; Carter R; Vincent S; Robertus L; Konstantinos A
Int J Tuberc Lung Dis; 2011 Apr; 15(4):551-2. PubMed ID: 21396218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
